sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_6132> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_6132> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB06151> ;
    a rdf:Statement ;
    rdfs:label "acetylcysteine solution usp is indicated as adjuvant therapy for patients with abnormal viscid or inspissated mucous secretions in such conditions as chronic bronchopulmonary disease chronic emphysema emphysema with bronchitis chronic asthmatic bronchitis tuberculosis bronchiectasis and primary amyloidosis of the lung acute bronchopulmonary disease pneumonia bronchitis tracheobronchitis pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies bronchograms bronchospirometry and bronchial wedge catheterization acetylcysteine solution usp administered orally is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen it is essential to initiate treatment as soon as possible after the overdose and in any case within 24 hours of ingestion" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB06151> bl:category bl:Drug .
}